Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women.
Group B Streptococcus (GBS) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. Further, GBS pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore, active immunization of women is an appealing strategy for the prevention of GBS disease in pregnant women and their infants during the first 3 months of infant life.
Group B Streptococcus
Biological: GBS III-TT-SSI
Biological: GBS III-TT-MPHL
|Study Design:||Masking: Double-Blind
Primary Purpose: Prevention
|Official Title:||Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines|
|Estimated Study Completion Date:||November 2005|
In this study 65 healthy, non-pregnant women will receive a single dose of one of two anti-streptococcal vaccinations. Both types of vaccinations are given in upper arm by injection into the muscle. To assess the vaccine effectiveness, patients have blood drawn and examined at weeks 4, 8 and 26, post-vaccination.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00008853
|United States, New York|
|New York, New York, United States, 10011|